PubMed Health⌕ Search

PubMed · 9465723

[Inhalation therapy--advantages and difficulties].

Abstract

Asthma bronchiale is a very common disease in our western countries. According to the SAPALDIA study (Swiss study on air pollution and lung diseases in adults) 7% of the Swiss population suffer from bronchial asthma or have complained once or several times about asthmatic symptoms. Roughly 3% of the Swiss suffer from chronic obstructive pulmonary disease. The standard treatment for both these conditions of bronchi and bronchioles is inhalation therapy. The enormous advantages of inhalation therapy, i.e. direct action of the drugs at the site of disease and the good acceptance by patients are opposed by the difficulties for correct inhalation. All devices, pressure nebulizers, powder delivery systems or aerosol dispensers have to be explained in depth to patients to achieve optimal results. Teaching of inhalation technique is the mission of the physician, in hospitals also of physiotherapists and nursing staff. Patients with chronic pulmonary diseases are cared for by the lung leagues whose collaborators are carefully trained for treating, instructing and surveilling patients.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

W Karrer. 1997-12-10. [Inhalation therapy--advantages and difficulties].. https://pubmed.ncbi.nlm.nih.gov/9465723/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Concurrent carbogen and radiation therapy in children with high-risk brainstem gliomas.

In an attempt to improve local control, we assessed the feasibility of the addition of 4 min of carbogen inhalation (as a radiosensitizer) to daily fractionated radiotherapy in pediatric patients with high grade and/or diffuse brainstem gliomas. Ten patients inhaled carbogen for >90% of the radiation treatments. Median survival time from start of therapy was 0.80 years. Carbogen inhalation did not appear to improve the dismal prognosis.

Administration, Inhalation↗

2. Advances in pharmacotherapy for COPD.

Chronic obstructive pulmonary disease (COPD) is the most common chronic lung disease in the world. In 1999, COPD ranked sixth among the most common causes of death and twelfth as a worldwide burden of disease. It has been estimated that by the year 2020 COPD will be the third leading cause of death and fifth as a worldwide burden of disease. Thus, COPD is a major medical problem and there is evidence that it is increasing throughout the world. Despite recognition of COPD as an important international health problem, COPD has been neglected among common diseases, with little investment in research on its underlying cellular and molecular mechanisms. Recently, global and Japanese guidelines for COPD have been published. These guidelines seem to be useful to improve the underdiagnosis and undertreatment of COPD. In this review, I describe briefly the current recommendation for pharmacological therapy of stable COPD according to the global and Japanese guidelines for COPD.

Administration, Inhalation↗